Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
51.25
-0.03 (-0.06%)
May 14, 2026, 9:40 AM EST
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
4.09
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
326.49B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Vaxart | 255.61M |
| Glass House Brands | 181.98M |
| Elite Pharmaceuticals | 140.12M |
| Tian'an Technology Group | 2.12M |
| Northwest Biotherapeutics | 1.38M |
| Silence Therapeutics | 839.00K |
Roche Holding AG News
- 2 days ago - Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030 - WSJ
- 2 days ago - Roche Holding AG Transcript: Roche Diagnostics Day 2026 - Transcripts
- 2 days ago - Roche gets second European approval for Alzheimer's test - Reuters
- 2 days ago - Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) - GlobeNewsWire
- 7 days ago - Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools - WSJ
- 7 days ago - Switzerland's Roche agrees to acquire US-based PathAI - Reuters
- 7 days ago - Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics - GlobeNewsWire
- 14 days ago - Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026 - Business Wire